PRMT1 and triple-negative breast carcinoma: Upon complete abrogation of endogenous PRMT1, and with the use of a PRMT1-specific inhibitor, cell viability was attenuated in triple-negative breast cancer cell lines (TNBC1 and TNBC2), one of the most aggressive forms of breast cancer.